Price History
Feb 9, 2026 — Mar 9, 2026Investment Snapshot
- P/B of 0.76 — trading below book value
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -858.4%
Mainz Biomed N.V. - Ordinary Shares (MYNZ) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $2 million . Key value metrics: P/B ratio 0.76, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Mainz Biomed N.V. - Ordinary Shares — Fundamental Analysis Summary
On financial health, MYNZ shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -858.4% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.08.
StockPik's composite Value Score for MYNZ is 64/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
MYNZ reports a high gross margin of 64.3% (sector average: 33.5%) and a negative operating margin of -2,091.2%.
MYNZ shows revenue declining at 0% year-over-year, with earnings growing at 18%.